Tesaro Is the Wrong Medicine for Glaxo

Bookmark
(Bloomberg Opinion) -- GlaxoSmithKline PLC’s ambitious but rather vague efforts to rebuild its pharma unit became more concrete Monday with its $5.1 billion acquisition of Tesaro Inc. But the deal ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.